Pharma Mar, S.A. (VIE:PHM)

Market Cap	1.58B +1.1%
Revenue (ttm)	221.39M +26.6%
Net Income	74.99M +187.0%
EPS	4.30 +188.7%
Shares Out	n/a
PE Ratio	21.07
Forward PE	26.42
Dividend	0.80 (0.94%)
Ex-Dividend Date	Jun 25, 2025

Volume	116
Average Volume	79
Open	88.85
Previous Close	89.75
Day's Range	88.85 - 89.90
52-Week Range	70.60 - 95.65
Beta	n/a
RSI	62.57
Earnings Date	Apr 24, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 505
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.